Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis DOI Creative Commons
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel

и другие.

Journal of Medical Virology, Год журнала: 2024, Номер 96(2)

Опубликована: Фев. 1, 2024

Abstract Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high risk of progression severe disease, based on a randomized trial in unvaccinated patients. Effectiveness vaccinated patients and against Omicron has not yet been confirmed by clinical data, but recent meta‐analysis suggested good real‐world effectiveness 12 studies. We updated this searching Medline Embase databases for studies assessing NR mortality, hospitalization, composite outcome hospitalization and/or death, published between October 1, 2022 May 22, 2023. Random effects subgroup analysis performed. A total 32 were included the meta‐analysis. Pooled RR effect disease 0.36 (95% confidence interval [CI]: 0.25−0.52), 0.43 (CI: 0.37−0.51), 0.52 0.45−0.61) 0.54 0.41−0.73), respectively. indicated lower mortality (RR: 0.55, CI: 0.45−0.68), similar or 0.52, 0.58, 0.66, respectively). This robustly confirms protective COVID‐19 outcomes.

Язык: Английский

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? DOI Open Access
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 162, С. 114367 - 114367

Опубликована: Фев. 6, 2023

Despite the need for novel, effective therapeutics COVID-19 pandemic, no curative regimen is yet available, therefore patients are forced to rely on supportive and nonspecific therapies. Some SARS-CoV-2 proteins, like 3 C-like protease (3CLpro) or major (Mpro), have been identified as promising targets antiviral drugs. The Mpro has a role in protein processing well pathogenesis of virus, could be useful therapeutic target. drug nirmatrelvir can keep from replicating through inhibiting Mpro. Nirmatrelvir was combined with another HIV inhibitor, ritonavir, create Paxlovid (Nirmatrelvir/Ritonavir). metabolizing enzyme cytochrome P450 A inhibited by ritonavir lengthen half-life nirmatrelvir, so rintonavir acts pharmacological enhancer. exhibits potent activity against current coronavirus variants, despite significant alterations viral genome. Nevertheless, there still several unanswered questions. This review summarizes literature efficacy treating infection, also their safety possible side effects.

Язык: Английский

Процитировано

99
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis DOI
Behnam Amani, Bahman Amani

Journal of Medical Virology, Год журнала: 2022, Номер 95(2)

Опубликована: Дек. 28, 2022

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for coronavirus disease 2019 (COVID-19). PubMed, Cochrane Library, Web Science, medRxiv, Google Scholar were searched identify relevant evidence up November 10, 2022. The reference lists key studies also scanned find additional records. quality was evaluated using tools assessing risk bias. Comprehensive Meta-Analysis software version 3.0 employed data analysis. Twenty-three involving 314 353 patients included in findings meta-analysis showed a significant difference between Paxlovid no-Paxlovid groups terms mortality rate (odds ratio [OR] = 0.25; 95% confidence interval [CI]: 0.14-0.45), hospitalization (OR 0.40; CI: 0.24-0.69), polymerase chain reaction negative conversion time (mean [MD] -2.46; -4.31 -0.61), or death 0.17; 0.06-0.46). However, no observed two COVID-19 rebound 0.84; 0.67-1.04), emergency department visit 0.75; 0.45-1.24), intensive care unit admission 0.37; 0.13-1.01), adverse events 2.20; 0.42-11.47). results present support treatment with COVID-19. Further research is needed investigate after treatment.

Язык: Английский

Процитировано

98
Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study DOI
Guangtong Deng, Daishi Li, Yuming Sun

и другие.

Journal of Medical Virology, Год журнала: 2023, Номер 95(4)

Опубликована: Апрель 1, 2023

Abstract Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19 patients. Nevertheless, real‐world effectiveness versus is still lacking, despite clinical trials showing their compared with matched controls. To compare treatments practice, we identified 2118 hospitalized patients, a follow‐up up to 38 days. After exclusions propensity score matching, included 281 recipients who did not receive oxygen therapy at admission. The lower crude incidence rate composite disease progression outcome (7.83 vs. 14.83 per 1000 person‐days, p = 0.026) all‐cause death (2.05 5.78 0.052) were observed among recipients. was associated risks (hazard ratio [HR]: 0.55; 95% confidence interval [CI]: 0.32–0.94) (HR: 0.40; CI: 0.16–1.04). In subgroup analyses, results retained significance patients aged <65 years, those having history disease, severe admission, receiving antibiotics. These findings suggest that treatment showed terms outcome.

Язык: Английский

Процитировано

56
An overview on the treatments and prevention against COVID-19 DOI Creative Commons

Yunes Panahi,

Armita Mahdavi Gorabi,

Sona Talaei

и другие.

Virology Journal, Год журнала: 2023, Номер 20(1)

Опубликована: Фев. 8, 2023

Abstract Background The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) continues to plague world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute distress syndrome), and death others. Although humans are currently being vaccinated with several candidate vaccines many countries, however, world still relying on hygiene measures, social distancing, approved drugs. Result There potential therapeutic agents pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, herbal agents. By an understanding of SARS-CoV-2 structure its infection mechanisms, vaccine candidates under development some various phases clinical trials. Conclusion This review describes agents, including biologic anti-inflammatory treatment patients. In addition reviewing that entered 4, 3, 2/3 trials, this also discusses platforms used develop COVID-19.

Язык: Английский

Процитировано

52
Efectividad y seguridad de nirmatrelvir + ritonavir en la Covid-19. Estudio NiRCoV DOI Creative Commons

V M González-Rodríguez,

M J Hernández-Arroyo,

C Rodríguez-Barrueco

и другие.

Medicina de Familia SEMERGEN, Год журнала: 2025, Номер 51(6), С. 102462 - 102462

Опубликована: Фев. 24, 2025

To analyze the effectiveness and potential safety concerns of Nirmatrelvir + ritonavir (NMV-r) (Paxlovid®) in adults with mild-moderate COVID-19 disease at high risk progression. Descriptive cross-sectional observational study. Castilla y León, Spain. 134 patients ≥18 years old progression to severe disease, who were treated between June September 2022 NMV-r. The most relevant drug interactions concomitant medication obtained from pharmaceutical validation records. From monitoring hospital admissions deaths 28 days following start treatment, information regarding treatment was obtained. 57.5% women, average age±SD 69.7±17.1, 68.0% received NMV-r first two symptoms, 74.6% home, 95.7% vaccinated. main condition for being immunocompromised (74.5%), followed by >65 old, vaccinated, but factors (21.2%). A total 62.9% had interactions, an average±SD 1.7±1.0 per patient. 2.2% required admission 3.0% died. has been effective preventing forms at-risk populations a vaccination rate. prevalence is high, however, collaboration family physicians pharmacists allows be used safely.

Язык: Английский

Процитировано

2
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis DOI
Huzaifa Ahmad Cheema, Uzair Jafar,

Aruba Sohail

и другие.

Journal of Medical Virology, Год журнала: 2023, Номер 95(2)

Опубликована: Янв. 6, 2023

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.

Язык: Английский

Процитировано

42
Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19 DOI Open Access
Yuan Gao, Zujin Luo, Shan Ren

и другие.

Journal of Infection, Год журнала: 2023, Номер 86(6), С. e158 - e160

Опубликована: Март 30, 2023

Язык: Английский

Процитировано

39
Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis DOI
Fangyuan Tian, Zhaoyan Chen,

Qiyi Feng

и другие.

Journal of Medical Virology, Год журнала: 2023, Номер 95(4)

Опубликована: Апрель 1, 2023

At present, there are some differences in the research results of nirmatrelvir-ritonavir compared with other antiviral drugs for treatment COVID-19 patients. We aimed to evaluate efficacy and safety impact different on short- long-term effects COVID-19. PubMed, Embase, CENTRAL (Cochrane Central Register Controlled Trials), Web Science, Google Scholar, MedRxiv were searched identify relevant studies from inception March 30, 2023. conducted a meta-analysis estimate patients outcomes. The RoB1 ROBINS-I used assess bias risk included studies. Revman 5.4 software was (PROSPERO Code No: CRD42023397816). Twelve included, including 30 588 patients, whom 13 402 received nirmatrelvir-ritonavir. showed that group had lower proportion than control terms mortality (odds ratio [OR] = 0.29, 95% confidence interval [CI]: 0.13-0.66), hospitalization (OR 0.44, CI: 0.37-0.53, short term; OR 0.52, 0.36-0.77, long term), disease progression 0.56, 0.38-0.83, 0.60, 0.48-0.74, nirmatrelvir ritonavir little difference group. Nirmatrelvir-ritonavir can reduce drugs. Further large-scale remain validate these findings.

Язык: Английский

Процитировано

32
The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients DOI Open Access
Ting-Hui Liu, Jheng‐Yan Wu, Po‐Yu Huang

и другие.

Journal of Infection, Год журнала: 2023, Номер 86(3), С. 256 - 308

Опубликована: Янв. 14, 2023

Язык: Английский

Процитировано

27
Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial DOI Creative Commons

Jianchao Xu,

Jinzhong Song,

Ziyu Xie

и другие.

Medicine, Год журнала: 2023, Номер 102(51), С. e36714 - e36714

Опубликована: Дек. 22, 2023

Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to evaluate impact Paxlovid on in-hospital outcomes and post-COVID-19 condition Chinese infected severe acute respiratory syndrome 2 (SARS-CoV-2) Omicron variant.This non-randomized clinical controlled trial recruited SARS-CoV-2 variant from designated hospital for treating COVID-19 between November 5 28, 2022, Shijiazhuang, China. Participants were administered (300 mg nirmatrelvir 100 orally) or standard treatment. The primary outcome was nucleic acid shedding time condition.A total 320 included, mean age 29.10 ± 7.34 years old. Two hundred received Paxlovid. Compared group, those group had a significantly shorter (3.26 1.80 vs 7.75 3.68 days, P < .001), days until negative swab test (1.74 1.15 5.33 2.91, first symptoms resolution (4.86 1.62 7.45 2.63, higher rate within 3 [138 (70.77%) 14 (11.67%), .001], [174 (89.23%) 26 (21.67%), 7 [185 (94.87%) 78 (65.00%), less likely [32 (18.60%) 30 (31.57%), = .016]. There no significant difference duration (43.00 26.00 49.00 26.34 .354) groups.Compared treatment, reduced time, test, resolution, as well improved condition.

Язык: Английский

Процитировано

26